“By joining the expertise from academia and pharmaceutical industry, and by analysing a collection of harmonised clinical and molecular data from nearly a million sufferers, unprecedented in scale and depth, ranging from multi-dimensional datasets on single cells (skin and blood) through to whole populations, atopic dermatitis and psoriasis will be identified as a series of different diseases rather than just one disease, each with a characteristic molecular ‘signature’.”

Prof. Stephan Weidinger
Christian-Albrechts-Universität zu Kiel
Coordinator

“BIOMAP presents a major opportunity to improve the lives of people with skin disease – we need information on why and who is going to develop severe disease, and also new approaches to treatment. Involving a Patient Advisory Group puts the needs of the patients at the heart of the project from the very beginning. By providing a European-wide platform for collaboration, BIOMAP will enable sharing of know-how and data about atopic dermatitis and psoriasis so that we can all work together like never before.”

Helen McAteer
Chief Executive of the Psoriasis Association
BIOMAP Patient Advisory Group

“BIOMAP will help us to better understand the relationships between inherited susceptibility, environmental factors, and molecular profiles, as well as the roles of each of these in onset and progression of the diseases.”

Dr Witte Koopmann
Co-project lead
LEO Pharma

“The findings from BIOMAP will drive rapid drug discovery to target causal mechanisms, and will pinpoint biomarkers which can support clinicians to decide who, when and how to intervene.”

Professor Catherine Smith
Co-coordinator
King’s College London